ClinicalTrials.gg
Not yet recruitingNCT06977308MISDEPUpdated Nov 13, 2026

A Multimodal Imaging Study of Dopamine in Early Psychosis

A Phase 1 interventional study of Methylphenidate (MPH) and [11C]raclopride in Clinical High Risk for Psychosis (CHR), sponsored by New York State Psychiatric Institute. Not yet recruiting. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by New York State Psychiatric Institute · Phase 1, Interventional, and Other

How we know

Updated Nov 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

The development of new treatments for psychosis, a psychiatric condition that is prevalent and highly disabling despite antipsychotic medications, has been limited, in part, by a lack of information from brain imaging studies during the period that leads to the development of psychotic symptoms. In this project the investigators will use Positron Emission Tomography (PET) and neuromelanin-sensitive magnetic resonance imaging (NM-MRI) to examine a brain chemical that is involved in schizophrenia called dopamine and where it first becomes abnormal. The investigators will use multimodal PET/MR imaging (i.e., [11C]raclopride w/MPH challenge and NM-MRI) in the same CHR patients. The investigators will recruit 115 clinical high risk individuals. All subjects will undergo [11C]raclopride w/methylphenidate challenge and neuromelanin-MRI imaging along with clinical assessments. Patients will be followed every 3 months for two years or until conversion to psychosis, whichever comes first, to assess for conversion to psychosis and clinical outcomes.

Read the detailed description

A large body of evidence suggests that abnormal striatal dopamine (DA) transmission is a key pathophysiological phenomenon in psychosis, mainly within the associative striatum (AST). However, it remains unclear where striatal DA abnormalities in psychosis start and whether they can be turned into a biomarker for development of psychotic illness. Early studies in individuals at clinical high-risk for psychosis (CHR) demonstrated that patients had higher [18F]DOPA uptake (i.e., DA synthesis capacity) in the AST compared to healthy control subjects (HC). One study reported that CHR individuals who developed a syndromal psychotic disorder had higher [18F]DOPA uptake than CHR individuals who did not progress. However, more recent work in larger samples has not replicated either finding. The investigators recently completed a feasibility study in which the investigators used [11C]-(+)-PHNO w/methylphenidate (MPH) challenge to examine intrasynaptic DA transmission in 14 CHR individuals and 14 HCs. The investigators found that intrasynaptic DA transmission was significantly elevated in the limbic/ventral striatum (VST), and not in any other ROI, in CHR individuals compared to HC. There was a strong correlation between intrasynaptic DA transmission in VST and total negative symptoms in the CHR group in which greater displacement was related to less negative symptoms. CHR subjects experienced no change in positive symptoms with MPH challenge, which demonstrates the safety of this technique. Additionally, our preliminary data with neuromelanin sensitive MRI (NM-MRI), a MR technique of measuring NM, a metabolite of DA, in different presynaptic nuclei (the substantia nigra [SN; the ventromedial portion of which projects to the AST] and ventral tegmental area [VTA; which projects to the VST]), demonstrate positive relationships between the contrast-to-noise ratio (CNR) of NM-MRI in the SN and positive symptoms in CHR and SCZ subjects. Taken together, these findings may reflect: 1) that striatal DA abnormalities in early psychosis progress in a temporo-spatial manner from VST to AST; 2) a clinical pattern in which negative symptoms are related to limbic DA transmission and positive symptoms reflect DA function in associative regions; 3) differences in biomarker (i.e., PHNO w/MPH challenge, NM-MRI, [18F]DOPA). This proposal will aim to advance the understanding of the nature, topography, and timing of striatal DA alterations in early psychosis by using multimodal PET/MR imaging (i.e., [11C]raclopride w/MPH challenge and NM-MRI) in the same CHR patients. The investigators will recruit 115 CHR individuals. All subjects will undergo [11C]raclopride w/MPH and NM-MRI imaging along with clinical assessments. Patients will be followed every 3 months for two years or until conversion to psychosis, whichever comes first, to assess for conversion to psychosis and clinical outcomes. Clarifying the nature, timing, and topography of DA abnormalities in early psychosis will greatly inform translational studies and could provide support for alternative initial therapeutic interventions to prevent progression in early psychosis.

02

Conditions studied

  • Clinical High Risk for Psychosis (CHR)

Keywords

  • clinical high risk for psychosis
03

In context

Lead sponsor

New York State Psychiatric Institute is the lead sponsor of 436 studies on the registry; 28 are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 46 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females between 18 and 30 years old
  2. Capacity to give
  3. Clinical High Risk (i.e., APSS, GRDS, BIPS)
  4. Antipsychotic free for 3 weeks before the PET scan
  5. Clinically stable enough for the study

Exclusion criteria

Exclusion Criteria:

  1. Any substance use disorder, of any severity, within the previous month (before PET scan; not including nicotine or caffeine)
  2. Any current use of substance of abuse besides THC/marijuana/cannabis/nicotine/caffeine (on day of PET only)
  3. Daily tobacco use
  4. Pregnancy
  5. Lactation
  6. Presence of insulin-dependent diabetes
  7. IQ \< 70 (i.e., WTAR \< 6)
  8. Acute risk for suicide (i.e., score of 4-5 within the previous month or 6 within the previous 3 months on the CSSRS) or violence, or history of severe violent behavior that may be exacerbated by methylphenidate
  9. Presence of metallic objects in the body
  10. Lifetime exposure to radiation in the workplace (i.e., being badged for radiation exposure), or exposure to radiation in the context of research protocol within the previous year that exceeds annual limits
  11. More than one risk factor for coronary artery disease (e.g., smoking, hyperlipidemia, sedentary lifestyle)
  12. Hypertension
  13. Presence of brain abnormalities. [For PET Scan Only]
  14. Previous adverse reaction to stimulants that would preclude receiving methylphenidate
  15. Presence or positive history of any cardiovascular disease, medical or neurological condition that would preclude methylphenidate administration or participation in this study
  16. A history of bipolar disorder Type 1, or any history of syndromal psychosis
  17. Lack of effective
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Methylphenidate

    Each subject will receive one oral dose of 60mg methylphenidate in between 2 PET scans with \[11C\]raclopride.

    Drug: Methylphenidate (MPH) · Drug: [11C]raclopride

Interventions

06

What researchers measure

Primary outcomes

  1. Dopamine transmission

    Delta BPND of \[11C\]raclopride in the Associative Striatum

    Time frame: From the first (before methylphenidate) to the second PET scans (one hour after methylphenidate) on Day 1 of the study

  2. Conversion to syndromal psychosis

    Development of a '6' on a P symptom of the SIPS

    Time frame: From administration of the study drug to either conversion to a syndromal psychotic disorder or 24 months, whichever comes first.

Secondary outcomes

  1. Positive Symptoms

    Total P symptom score on the SIPS

    Time frame: At time zero before administration of methylphenidate

  2. Negative Symptoms

    Total N symptom score on the SIPS

    Time frame: At time zero before administration of methylphenidate

  3. Dopamine Transmission in the ventral striatum

    Delta BPND (\[11C\]raclopride) in the Ventral striatum

    Time frame: From the first (before methylphenidate) to the second PET scans (one hour after methylphenidate) on Day 1 of the study

Other outcomes

  1. Baseline dopamine

    Neuromelanin MRI in midbrain at baseline

    Time frame: At time zero before administration of methylphenidate

  2. Change in positive symptoms

    Change in total SIPS positive symptoms

    Time frame: From time zero before administration of methylphenidate to either conversion to a syndromal psychotic disorder or 24 months, whichever comes first.

  3. Change in negative symptoms

    Change in total N symptoms on the SIPS

    Time frame: From time zero before administration of methylphenidate to either conversion to a syndromal psychotic disorder or 24 months, whichever comes first.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Girgis RR, Slifstein M, Brucato G, Kegeles LS, Colibazzi T, Lieberman JA, Abi-Dargham A. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study. Mol Psychiatry. 2021 Jun;26(6):2504-2513. doi: 10.1038/s41380-020-00934-w. Epub 2020 Nov 5. PubMed 33154566 ↗

Individual participant data

Plan to share: Yes — Data will be shared via the NIH data archive.

Time frame: Data will be shared after the study has been completed, as per NIH guidelines.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2029, 33 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 18, 2025
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Oct 1, 2029
CompletionEst.
Oct 1, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Oct 1, 2026→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06977308
Responsible party
Ragy Girgis (Professor of Clinical Psychiatry, New York State Psychiatric Institute) — Principal investigator
First posted
May 18, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Oct 1, 2029 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Ragy Girgis, MD
Contact
ragy.girgis@nyspi.columbia.edu
646-774-5553

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methylphenidate · Raclopride c-11

Start the discussion